Clinical trial · Observational
DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
REGISTRY PLATFORM INTO DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
NCT05254119CI-TRIAL-00075740REGISTURK-LUNGunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Small-cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Frequency of molecular/mutational analysis
- timeFrame
- throughout of treatment, 36 months
- description
- To collect data on the frequency of molecular/mutational biomarker testing
- measure
- Type of molecular/mutational analysis
- timeFrame
- throughout of treatment, 36 months
- description
- To collect data on the type of molecular/mutational biomarker testing
Secondary outcomes (6)
- measure
- Type of treatment
- timeFrame
- throughout of treatment, 36 months
- description
- To describe systemic treatments and sequential treatments applied in real-life practice.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient histopathologically diagnosed with non-small cell lung cancer or small cell lung cancer 2. Written informed consent no later than six weeks after start of first-line treatment 3. Age ≥ 18 years Exclusion Criteria: * Volunteers participating in a research program for non-small cell or small cell lung cancer that includes interventions outside of routine clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.